Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events On December 10, 2025, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partner
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 1.1* Underwriting Agreement, between the Company and Leerink Partners LLC,